ArticleKidney diseases (Basel, Switzerland)
Additive Association of
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to investigate the interaction between the Methods: This retrospective case-control study involved 35,280 adults from the Taiwan Precise Medicine Initiative database. We examined the prevalence of gout and ultrasound confirmed nephrolithiasis as the primary and secondary outcome. Logistic regression models were used to explore the associations between genetic variants, serum uric acid levels, incident gout, and nephrolithiasis. Results: The frequencies of the rs4148155 variant and the rs75786299 variant were 63.2% and 3.7%, respectively. Among participants, 7,056 were gout, and 4,110 had nephrolithiasis. Multivariable odds ratios (ORs) for gout were 1.67 and 1.96 among rs4148155 and rs75786299 carriers, respectively ( Conclusion: The study highlights a significant association between the rs4148155, rs75786299 variants and the development of gout and nephrolithiasis, indicating an additive risk among carriers. These findings support precision healthcare approaches for individuals with risk genetic variants to target hyperuricemia, gout, and systemic comorbidities, ultimately preventing nephrolithiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.